0000000000352344

AUTHOR

Federico Chiurazzi

showing 2 related works from this author

PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC

2021

The current COVID-19 pandemic requires revisiting our current approach to major blood disorders, including ITP (Immune Thrombocytopenia), stirring  up the production of several disease-specific practical guidelines. This report describes an updated version of consensus-based practical guidelines on the management of ITP, adapted to the Italian health system and social context.  It highlights the role of the hematologist in offering guidance for choosing differentiated approaches in relation to specific circumstances and is intended to provide them with a useful tool for sharing the decision-making process with their patients.
 Probably, the greatest risk to avoid for a patient with sus…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)business.industrymedicine.medical_treatmentSplenectomySocial environmentHematology030204 cardiovascular system & hematologyImmune thrombocytopenia03 medical and health sciencesTherapeutic approach0302 clinical medicineInfectious DiseasesBlood Disorderhemic and lymphatic diseasesPandemicmedicine030212 general & internal medicineHematologistIntensive care medicinebusinessMediterranean Journal of Hematology and Infectious Diseases
researchProduct

Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations

2021

Introduction: In patients with primary immune thrombocytopenia (ITP), a short course of steroids is routinely given as first-line therapy. However, the response is often transient and additional therapy is usually needed. Thrombopoietin receptor agonists (TPO-RAs) are frequently used as second-line therapy, although there is little clinical guidance on the timing of their administration and on tapering/discontinuation of the drug. To provide clinical recommendations, we used the Delphi technique to obtain consensus for statements regarding administration and on tapering/discontinuation of second-line TPO-RAs among a group of Italian clinicians with expertise in management of ITP. Methods: T…

Thrombopoietin Receptor Agoniststherapybusiness.industryconsensus Delphi immune thrombocytopenia management second line therapy thrombopoietin receptor agonistsfood and beveragesconsensus; Delphi; immune thrombocytopenia; management; second line; therapy; thrombopoietin receptor agonistsHematologySettore MED/15DelphiImmune thrombocytopeniaSecond lineimmune thrombocytopeniaconsensusImmunologyconsensuMedicinethrombopoietin receptor agonistsDiseases of the blood and blood-forming organsIn patientsecond lineRC633-647.5businessmanagementOriginal Research
researchProduct